|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplemental Table 3.** PICRUSt-predictedKEGG pathways significantly associated with TGFβ2 (FDR adjusted p-value<0.05). Pathways are ordered by direction of association and effect size. | | | | | |
| **KEGG Pathway** | | | | **Estimate\*** | **FDR-adjusted p-value** |
| **Positive Association with TGFβ2** | | | | | |
| Metabolism | Lipid Metabolism | Steroid biosynthesis | | 3.13 | 8.56E-06 |
| Metabolism | Lipid Metabolism | Fatty acid elongation in mitochondria | | 3.13 | 1.07E-02 |
| Metabolism | Biosynthesis of Other Secondary Metabolites | Caffeine metabolism | | 3.07 | 2.90E-03 |
| Organismal Systems | Endocrine System | Renin-angiotensin system | | 2.96 | 6.49E-07 |
| Metabolism | Biosynthesis of Other Secondary Metabolites | Flavonoid biosynthesis | | 2.37 | 2.40E-13 |
| Organismal Systems | Immune System | Fc gamma R-mediated phagocytosis | | 2.35 | 2.90E-03 |
| Organismal Systems | Endocrine System | GnRH signaling pathway | | 2.35 | 2.90E-03 |
| Cellular Processes | Transport and Catabolism | Endocytosis | | 2.35 | 2.90E-03 |
| Human Diseases | Immune System Diseases | Systemic lupus erythematosus | | 2.30 | 1.78E-05 |
| Organismal Systems | Environmental Adaptation | Circadian rhythm - plant | | 2.16 | 6.30E-05 |
| Human Diseases | Neurodegenerative Diseases | Parkinson's disease | | 1.57 | 6.06E-05 |
| Organismal Systems | Circulatory System | Cardiac muscle contraction | | 1.57 | 6.06E-05 |
| Human Diseases | Infectious Diseases | Shigellosis | | 1.55 | 2.90E-03 |
| Organismal Systems | Endocrine System | Melanogenesis | | 0.99 | 1.34E-07 |
| Metabolism | Biosynthesis of Other Secondary Metabolites | Betalain biosynthesis | | 0.99 | 1.34E-07 |
| Human Diseases | Cardiovascular Diseases | Hypertrophic cardiomyopathy (HCM) | | 0.99 | 9.73E-279 |
| Metabolism | Biosynthesis of Other Secondary Metabolites | Isoflavonoid biosynthesis | | 0.93 | 3.62E-150 |
| Human Diseases | Infectious Diseases | Influenza A | | 0.42 | 2.32E-02 |
| Human Diseases | Cancers | Small cell lung cancer | | 0.42 | 2.32E-02 |
| Human Diseases | Infectious Diseases | Toxoplasmosis | | 0.42 | 2.32E-02 |
| Human Diseases | Cardiovascular Diseases | Viral myocarditis | | 0.42 | 2.32E-02 |
| Cellular Processes | Cell Growth and Death | p53 signaling pathway | | 0.42 | 2.32E-02 |
| Human Diseases | Cancers | Colorectal cancer | | 0.42 | 2.32E-02 |
| Cellular Processes | Cell Growth and Death | Meiosis - yeast | | 0.04 | 0.00E+00 |
| **Negative Association with TGFβ2** | | | | | |
| Human Diseases | Infectious Diseases | Vibrio cholerae infection | -1.34 | | 1.54E-03 |
| Metabolism | Lipid Metabolism | alpha-Linolenic acid metabolism | -0.71 | | 1.67E-02 |
| Human Diseases | Infectious Diseases | Pertussis | -0.66 | | 1.84E-02 |
| Metabolism | Metabolism of Terpenoids and Polyketides | Biosynthesis of siderophore group nonribosomal peptides | -0.63 | | 2.59E-02 |
| \**Difference in log mean abundance for a 1-unit increase in log(TGFβ2).* | | | | | |